chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itching at the injection site; Patient started experiencing pain, itching, and redness at the injection site on the day of vaccination, and now the redness size increased from the size of a penny to a silver dollar coin; Redness at the injection site increased from the size of a penny to a silver dollar coin; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (Itching at the injection site), INJECTION SITE PAIN (Patient started experiencing pain, itching, and redness at the injection site on the day of vaccination, and now the redness size increased from the size of a penny to a silver dollar coin) and INJECTION SITE ERYTHEMA (Redness at the injection site increased from the size of a penny to a silver dollar coin) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced INJECTION SITE PRURITUS (Itching at the injection site), INJECTION SITE PAIN (Patient started experiencing pain, itching, and redness at the injection site on the day of vaccination, and now the redness size increased from the size of a penny to a silver dollar coin) and INJECTION SITE ERYTHEMA (Redness at the injection site increased from the size of a penny to a silver dollar coin). At the time of the report, INJECTION SITE PRURITUS (Itching at the injection site), INJECTION SITE PAIN (Patient started experiencing pain, itching, and redness at the injection site on the day of vaccination, and now the redness size increased from the size of a penny to a silver dollar coin) and INJECTION SITE ERYTHEMA (Redness at the injection site increased from the size of a penny to a silver dollar coin) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant drugs were reported. No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: No new information was reported.
Swollen lymph node under left arm; This is a spontaneous report from a contactable consumer (patient) A 46-years-old male patient received the first dose of BNT162B2 Pfizer-BioNTech COVID-19 mRNA Vaccine, Lot number EL8982, in Hospital, via an unspecified route of administration in right arm, on 18Jan2021 (at 46 years of age) at single dose for COVID-19 immunization. Medical history included seasonal allergy (pollen) and allergy to cats, both from an unknown date. The patient has not been tested for COVID-19 since the vaccination. Concomitant medication included Vitamin D3 and Multi vitamins. On 27Jan2021 the patient experienced swollen lymph node under left arm. No treatment was administered for the event. The patient was recovering from the reported event at the time of the report.
Patient was due to receive his 2nd dose of Moderna and the nurse gave him Pfizer for his 2nd dose. Patient did not have an adverse reaction after the Pfizer dose was given to him.
8/20/2021: COVID19 pos 8/22/2021: admitted to hospital with SOB and COPD flare up pt received O2 and dexamethasone in hospital 8/24/2021: discharged to home
genital warts have now returned; but the genital warts have now returned; This spontaneous report was received from a pharmacist referring to a 53 years old male patient. The patient's concurrent conditions included type 2 diabetes mellitus, hypertension, hyperlipidaemia and human immunodeficiency virus (HIV) infection (reported as HIV). The patient's medical history included human papillomavirus (HPV) with genital warts, resulting in prior surgeries. Concomitant therapies included testosterone(ANDROGEL), hydroxyzine (reported as hydrozyzine), duloxetine hydrochloride(CYMBALTA), cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide fumarate(GENVOYA), lisinopril and metformin hydrochloride, sitagliptin phosphate(JANUMET).  In 2018 (reported as last year), at the age of 53 years old, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) series (strength, dose, lot # and expiration date were not reported) intramuscularly for prophylaxis (indication reported as HPV). The last dose was being administered on 02-AUG-2018. In 2018 (reported during the two months following the last dose of the series), the patient did not have any outbreaks but the genital warts had now returned, which might require another surgery. Treatment was not given. None lab diagnostics or studies was performed. The patient sought medical attention.  The outcome of anogenital warts and vaccination failure was reported as not recovered. The causality assessment was not provided by the reporter.
Cold symptoms and lymph adenopathy prior to menstrual cycle period (menses began). Admitted to the hospital for diagnosis and treatment 11/07-11/09. Saw nephrologist. Began Predinsone. Follow up report states "Continues with Nephrotic syndrome, S/P Renal Biopsy, Minimal change, Ongoing treatment required-Pediatric Nephologist."
PATIENT WAS GIVENT THE MONOVALENT VACCINE INSTEAD OF THE BIVALENT VACCINE
exhausted and a temp of 99.  My normal is 97.4.  I laid down and slept until morning and felt fine.
5 min. after vaccines administered mom came out of room and stated child had a rash. Face blotchy and red. (R) arm sl. swollen and red. Blotchiness spread a little to trunk/arm.
Headache; Flu; Arm ill; This is a spontaneous report from a non-contactable consumer (patient) through a Pfizer-sponsored program. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number and expiration date were not reported) as dose 1, single, with route of administration and therapy date unspecified, for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient had headache, flu and arm was ill. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Tested positive for COVID; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST FALSE POSITIVE (Tested positive for COVID) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. O11J2OA) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced SARS-COV-2 TEST FALSE POSITIVE (Tested positive for COVID). At the time of the report, SARS-COV-2 TEST FALSE POSITIVE (Tested positive for COVID) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jan-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.; Sender's Comments: Very limited information regarding this event has been provided at this time.  Further information has been requested.
Information has been received from a physician via a company representative, concerning a female patient who was vaccinated with either a first dose or second of GARDASIL. Subsequently the patient experienced nausea after vaccination. The patient recovered within a day. The patient sought unspecified medical attention. This is in follow-up to report(s) previously submitted on 3/14/2007.  Initial and follow-up information has been received from a physician, concerning a female patient who was vaccinated with either a first or second dose of GARDASIL (date not specified).  The physician stated the patient's father mentioned that his daughter experienced nausea after vaccination.  The physician reported that the patient recovered within a day.  The physician did not believe the nausea was caused by GARDASIL.  The patient sought unspecified medical attention.  No further information is expected.
After the 2nd dose I had the vaccine at 12noon and at 6pm I got sick and until the next morning. With fever, headache, nausea, chills just about all the COVID symptoms and it was short. It lasted about 12 hours or so. When I first got sick, the symptoms weren't bad but it was like the flu. I had to make myself get up and sleep. Didn't have problems breathing initially. It wasn't until day 10 that I couldn't breath or catch my breath. I started seeing the doctor every Friday until I could get it under control. They gave me a nebulizer, and other things until 2-3 months when I could get it under control.
Feeling of slow motion; Fever; Chills; Upset stomach; Headache; severe injection site pain, swelling, and redness; severe injection site pain, swelling, and redness; severe injection site pain, swelling, and redness; This is a spontaneous report from a non-contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Jun2021 at 09:15 (at the age of 18-years-old), as a single dose for COVID-19 immunisation. Medical history included autoimmune disorder, hypothyroidism and irritable bowel syndrome. Concomitant medications included levothyroxine sodium (SYNTHROID), dicycloverine hydrochloride (DICYCLOMINE HYDROCHLORIDE), duloxetine (MANUFACTURER UNKNOWN) and cetirizine hydrochloride (ZYRTEC); all for unspecified indication from unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had no allergies to food, medications, or other products. On 29Jun2021 at 09:15, the patient had feeling of slow motion and experienced fever, chills, upset stomach, headache, severe injection site pain, swelling, and redness. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events feeling of slow-motion fever, chills, upset stomach, headache, severe injection site pain, swelling, and redness was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected
having a hard time breathing; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (having a hard time breathing) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (having a hard time breathing). The patient was treated with FEXOFENADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (ALLEGRA-D [FEXOFENADINE;PSEUDOEPHEDRINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, DYSPNOEA (having a hard time breathing) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
This case was reported by a physician via call center representative and described the occurrence of vomiting in a 4-year-old male patient who received FLUARIX Quadrivalent (batch number 29PD2, expiry date 30th June 2017). Concurrent medical conditions included developmental delay. Concomitant products included PROQUAD. On 15th September 2016, the patient received the 1st dose of FLUARIX Quadrivalent. On 15th September 2016, 50 min after receiving FLUARIX Quadrivalent, the patient experienced vomiting. On an unknown date, the outcome of the vomiting was unknown. It was unknown if the reporter considered the vomiting to be related to FLUARIX Quadrivalent. Additional details were provided as follows: On 15th September 2016, at 9 hours, the patient received FLUARIX Quadrivalent in left deltoid and at 9.50 hours, he vomited right after given the flu shot. On the same day, the patient also received PROQUAD in left deltoid concomitantly. The reported lot number (29PZ2) for FLUARIX did not exist and was updated to 29PD2 as per the sales database.
SUSPECTED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a patient of unspecified age, sex, race and ethnicity. The patient's height, and weight were not reported. The patient's concurrent conditions included: hypertension. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 201A21A expiry: UNKNOWN) dose was not reported, 1 total administered at left arm on 09-APR-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1).  The patient additionally received non-company suspect vaccine included: Pfizer Biontech (tozinameran) (dose number in series 2) (form of admin, route of admin were not reported, batch number: FF8841 expiry: UNKNOWN) dose was not reported, administered at left arm on 04-DEC-2021 for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (dose number in series 2). Concomitant medications included Excedrin Migraine (acetylsalicylic acid/caffeine/paracetamol), amlodipine, and losartan for unspecified indication. On an unspecified date in FEB-2023, the patient experienced covid-19 infection (suspected covid-19 infection) (dose number in series 2) for which patient received non-company suspect drug Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin, batch number and expiry date were not reported) dose and frequency were not reported from 22-FEB-2023 to 27-FEB-2023 for covid-19 treatment.  On 07-MAR-2023 the patient experienced covid-19 rebound infection (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s, and tozinameran was not applicable; and action taken with nirmatrelvir/ritonavir was not reported. The patient had not recovered from suspected covid-19 infection, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious.
Pt had welt at site of injection with 3 1/2 inches started within 24 hours. Pt took BENADRYL & CLARITIN around 5/13/11 and it started resolving. Still treating as of 5/16/11, not much better.
Information has been received from an LPN concerning a 26 year old female co-worker who was "unsure" whether as a child, was vaccinated with a dose of MMRII. On 3/4/02, the pt presented with a swollen parotid gland, one side only. It was noted that the pt did not have a sore throat. The pt saw a physician who was unsure of the cause of her swollen parotid glands. It was reported that the physician did not order any lab tests, including a strept test. A possible dx of mumps was noted. The physician ordered an antibiotic and the pt recovered approx. 10 days later. No further info is expected.
lethargic, body aches, ax t102-103, vomited 5APR early PM followed by improved physical condition; symptomatic for 24 hr;tx APAP
Pt with swelling and pain at site (R deltoid) of injection. -SOB, -LDC, -fever, -lip swelling. Reaction occurred on day of injection (8/15/02) and pt presented on 8/20/02 with resolving symptoms.
after 2nd shot. Side effects began with light headedness and left arm pain (greater than 1st shot) , then became  nauseous, very intense head and neck pain.  Then had bouts of feeling very cold, then hot with slight fever.  This lasted 48 hours
On about 10/24/11 onset of weakness, headaches, lack of balance. On about 11/13/11, severe headaches, slurring of speech, lack of balance, weakness of tongue, throat & eyes blurry. Emergency rm. Hosp 11/14/11. Another hosp (IVIG) GSB (dia.).
since getting my booster shot I have developed a cough starting 04Nov2022; product=COVID 19, brand=Pfizer, is bivalent=False, Administration date=06Oct2022; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2022 as dose 2 (booster), single (Lot number: GJ6665) at the age of 35 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: covid 19 janssen (Dose Number: 1, Batch/Lot No: 1855191, Location of injection: Arm Left), administration date: 15Dec2021, when the patient was 34-year-old, for COVID-19 immunization. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 06Oct2022, outcome "unknown", described as "product=COVID 19, brand=Pfizer, is bivalent=False, Administration date=06Oct2022"; COUGH (medically significant) with onset 04Nov2022, outcome "not recovered", described as "since getting my booster shot I have developed a cough starting 04Nov2022". The event "since getting my booster shot i have developed a cough starting 04nov2022" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (09Dec2022) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of cough.  Clinical course: The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. She have no other illnesses. Since getting her booster shot she had developed a cough starting 04Nov2022 and have been treated with antibiotics, advent inhaler, abuterol, and cough Medications and my cough will not go away. She had medications and her cough will not go away. She had never before prior to the vaccine had an issue getting over a cough. Patient treated with antibiotics, breathing treatments, cough suppress.
Aside from the soreness of the left arm where I was injected, the left side of my neck and esophagus is sore and I have numbness on the left side of my face. The numbness is on the left jaw, the cheek, the eye brow and forehead.  It's itchy and tingly.  It feels somewhat like when a part of the body is coming out of being asleep and it tingles.  This is the second day of the numbness. I did not expect this reaction to this COVID-19 vaccination and I have never had such a reaction to vaccinations in the past.  I read on the internet of people getting Bell's palsy from the COVID-19 shot and wondered if this is similar.  With this reaction from the first COVID-19  shot, I'm concerned what my reaction might be if/when I have the 2nd vaccination.
Second shot was administered and immediately patient became unresponsive for approximately one minute. Was observed to continue to breath without assistance. Regained consciousness with no intervention.
Bradycardia, dizziness, abdominal pain, fatigue, headache. Was not aware of the bradycardia until I went to the emergency room, other symptoms were present Apr 10 - 15. Hospital visit was 13 Apr.  treatment was rest, over the counter medications and follow up with doctor.
Initial information received on 20-Mar-2019 regarding an unsolicited valid non-serious case received from a consumer. This case involves a 36 years old female patient who cannot move her arm parallel to her shoulder, hot flashes, nauseous, dizzy, lightheaded, her arm hurts, like she pulled a muscle or was punched, she feels like she moves in and out of being really tired and then will feel ok, chills and low grade fever of 98.9 f, while she received vaccine TENIVAC. The patients past medical history, concomitant medication and family history were not provided. On 18-Mar-2019, the patient received a 0.5ml dose of suspect TENIVAC lot U6091AA, expiry date 12-Oct-2020 via unknown route in the left deltoid. On an unknown date, the patient developed a non-serious she cannot move her arm parallel to her shoulder (mobility decreased) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious hot flashes (hot flush) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious nauseous (nausea) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious dizzy, lightheaded (dizziness) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious her arm hurts, like she pulled a muscle or was punched (pain in extremity) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious she feels like she moves in and out of being really tired and then will feel ok (fatigue) with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious chills with unknown latency following the administration of TENIVAC. On an unknown date, the patient developed a non-serious low grade fever of 98.9 f (pyrexia) with unknown latency following the administration of TENIVAC. The patient visited a Clinic. Lab data was not provided. Final diagnosis was low grade fever of 98.9 f, chills, she feels like she moves in and out of being really tired and then will feel ok, her arm hurts, like she pulled a muscle or was punched, dizzy, lightheaded, nauseous, hot flashes and she cannot move her arm parallel to her shoulder. The patient was treated with IBUPROFEN and TYLENOL. The patient outcome is reported as Unknown for dizzy, lightheaded, as Unknown for nauseous, as Unknown for low grade fever of 98.9 f, as Unknown for chills, as Unknown for hot flashes, as not recovered for her arm hurts, like she pulled a muscle or was punched, as not recovered for she cannot move her arm parallel to her shoulder and as Unknown for she feels like she moves in and out of being really tired and then will feel ok. List of documents held by sender- none.
Systemic: Allergic: Difficulty Breathing-Medium, Systemic: shortness of breath/pain in legs-Medium
pt recv vax in 1997;7/11/99 exp rt sided facial & eye pain;fever 104;painful papule near rt zygomatic area; hosp w/ h/a, fever, rt sided eye pain; addl lesions devel;Dx herpes zoster of rt trigeminal nerve(opthalmic division);
This spontaneous report as received via a company representative from a physician's receptionist referring to her 13 year old daughter. The patient's concurrent conditions, medical histories and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with a dose of GARDASIL (lot #, expiration date and dose were unknown) or GARDASIL 9 (lot #, expiration date and dose were unknown) intramuscularly, at the clinic by an unspecified physician. The reporter was unable to confirm which one the vaccine the patient received. On unknown dates, the patient experienced fatigue, bone pain and body aches. On an unknown date, the patient was treated at a hospital by another physician. The outcome of the events was reported as recovered (dates unknown). The reporter did not assess the causality. Additional information has been requested.